Veterans Health Library

(2.2)DOSAGE FORMS AND STRENGTHSVardenafil orally disintegrating tablet 10 mg: White to off-white, round, biconvex, orally disintegrating tablets (not scored) (3)CONTRAINDICATIONSWARNINGS AND PRECAUTIONSCardiovascular Effects: Patients should not use vardenafil orally disintegrating tablet if sex is inadvisable due to cardiovascular status. (5.1)Strong and Moderate CYP3A4 Inhibitors: Do not use vardenafil orally disintegrating tablet in patients taking strong or moderate CYP3A4 inhibitors. (5.2, 7.2)Risk of Priapism: In the event that an erection lasts more than 4 hours, the patient should seek immediate medical assistance.

8.7 Renal Impairment

(5.3)Effects on the Eye: Patients should stop use of vardenafil orally disintegrating tablet, and seek medical attention in the event of sudden loss of vision in one or both eyes, which could be a sign of non arteritic anterior ischemic optic neuropathy (NAION). Vardenafil orally disintegrating tablet should be used with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION. Patients with a “crowded” optic disc may also be at an increased risk of NAION. (5.4, 6.2)Sudden Hearing Loss: Patients should stop vardenafil orally disintegrating tablet and seek medical attention in the event of sudden decrease or loss in hearing.

(5.5, 6.2)Alpha-Blockers: Caution is advised when PDE5 inhibitors are coadministered with alpha-blockers. In some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (for example, fainting). In patients taking alpha-blockers, do not initiate vardenafil therapy with vardenafil orally disintegrating tablet.

7.1 Potential for Pharmacodynamic Interactions with vardenafil orally disintegrating tablet

Sexual stimulation is required for a response to treatment.Vardenafil orally disintegrating tabletshould be placed on the tongue where it will disintegrate. It should be taken immediately upon removal from the blister.Those patients who require a lower or higher dose of vardenafil need to be prescribed vardenafil film-coated tablets [see Patient Counseling Information (17)] .2.3 Use in Special PopulationsHepatic Impairment: Do not use vardenafil orally disintegrating tabletin patients with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment [see Warnings and Precautions (5.8) and Clinical Pharmacology (12.3)] .Renal Impairment: Do not use vardenafil orally disintegrating tablet in patients on renal dialysis [see Warnings and Precautions (5.9) and Clinical Pharmacology (12.3)].2.4 Concomitant MedicationsNitrates: Concomitant use with nitrates in any form is contraindicated [see Contraindications (4.1)] .Guanylate Cyclase (GC) Stimulators, such as riociguat: Concomitant use is contraindicated [see Contraindications (4.2)].CYP3A4 Inhibitors: Do not use vardenafil orally disintegrating tablet with strong or moderate CYP3A4 inhibitors such as cobicistat ,ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, atazanavir, clarithromycin and erythromycin [see Warnings and Precautions (5.2) and Drug Interactions (7.2)].Alpha-Blockers: In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest recommended starting dose. Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure in patients taking a phosphodiesterase (PDE5) inhibitor including vardenafil. Lower doses of vardenafil film-coated tablets should be used as initial therapy in these patients [see Dosage and Administration (2.4)] .Patients taking alpha-blockers who have previously used vardenafil film-coated tablets may change to vardenafil orally disintegrating tablet at the advice of their healthcare provider. [See Warnings and Precautions (5.6) and Drug Interactions (7.1).

What is vardenafil used for?

]A time interval between dosing should be considered when vardenafil orally disintegrating tablet is prescribed concomitantly with alpha-blocker therapy [see Clinical Pharmacology (12.2)]. (2.4,5.6)QT Prolongation: Patients with congenital QT syndrome or taking class IA or III antiarrhythmics should avoid using vardenafil orally disintegrating tablet.

• The medication is available by prescription only.
• Liquid form allows flexible dosing compared to tablets.
• Usage instructions should be followed exactly.

(5.7, 12.2)Phenylketonurics: Each vardenafil orally disintegrating tablet contains 3.36 mg phenylalanine per tablet, which could be harmful for patients with phenylketonuria. (5.12)ADVERSE REACTIONSAdverse reactions reported by ≥ 2% of patients treated with vardenafil orally disintegrating tablet: Headache, flushing, nasal congestion, dyspepsia, dizziness, back pain. (6.1)To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc., at 1-888-943-3210 or 1-855-926-3384 or FDA at 1-800-FDA-1088 or INTERACTIONSVardenafil orally disintegrating tablet can potentiate the hypotensive effects of nitrates, alpha-blockers, and antihypertensives.

Further information

(2.4,5.6)QT Prolongation: Patients with congenital QT syndrome or taking class IA or III antiarrhythmics should avoid using vardenafil orally disintegrating tablet. (5.7, 12.2)Phenylketonurics: Each vardenafil orally disintegrating tablet contains 3.36 mg phenylalanine per tablet, which could be harmful for patients with phenylketonuria. (5.12)ADVERSE REACTIONSAdverse reactions reported by ≥ 2% of patients treated with vardenafil orally disintegrating tablet: Headache, flushing, nasal congestion, dyspepsia, dizziness, back pain. (6.1)To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc., at 1-888-943-3210 or 1-855-926-3384 or FDA at 1-800-FDA-1088 or INTERACTIONSVardenafil orally disintegrating tablet can potentiate the hypotensive effects of nitrates, alpha-blockers, and antihypertensives. (7.1)Do not use vardenafil orally disintegrating tablet with moderate or strong CYP3A4 inhibitors as coadministration will result in significant online levitra sale increases in plasma vardenafil concentrations.

Photodegradation of fluoroquinolones in surface water and antimicrobial activity of the photoproducts

(7.2)USE IN SPECIFIC POPULATIONSSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.Revised: 1/2025 Warnings and Precautions (5.4) 08/2017 Vardenafil is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction. Vardenafil orally disintegrating tablet is not interchangeable with vardenafil 10 mg film-coated tablets (LEVITRA). Vardenafil orally disintegrating tablet is taken as needed, orally, approximately 60 minutes before sexual activity. The maximum recommended dosing frequency is one tablet per day. Vardenafil orally disintegrating tablet should be placed on the tongue where it will disintegrate. (7.1)Do not use vardenafil orally disintegrating tablet with moderate or strong CYP3A4 inhibitors as coadministration will result in significant online levitra sale increases in plasma vardenafil concentrations. (7.2)USE IN SPECIFIC POPULATIONSSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.Revised: 1/2025 Warnings and Precautions (5.4) 08/2017 Vardenafil is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction. Vardenafil orally disintegrating tablet is not interchangeable with vardenafil 10 mg film-coated tablets (LEVITRA).

5.7 Congenital or Acquired QT Prolongation

Water Res.

Vardenafil orally disintegrating tablet is taken as needed, orally, approximately 60 minutes before sexual activity. The maximum recommended dosing frequency is one tablet per day.

Treating Priapism (An Erection That Lasts Too Long)

Vardenafil orally disintegrating tablet may be taken with or without food. Vardenafil orally disintegrating tablet 10 mg: White to off-white, round, biconvex, orally disintegrating tablets (not scored) (3) Cardiovascular Effects: Patients should not use vardenafil orally disintegrating tablet if sex is inadvisable due to cardiovascular status. Strong and Moderate CYP3A4 Inhibitors: Do not use vardenafil orally disintegrating tablet in patients taking strong or moderate CYP3A4 inhibitors. Risk of Priapism: In the event that an erection lasts more than 4 hours, the patient should seek immediate medical assistance. Effects on the Eye: Patients should stop use of vardenafil orally disintegrating tablet, and seek medical attention in the event of sudden loss of vision in one or both eyes, which could be a sign of non arteritic anterior ischemic optic neuropathy (NAION).

Pregnancy Categories

Sudden Hearing Loss: Patients should stop vardenafil orally disintegrating tablet and seek medical attention in the event of sudden decrease or loss in hearing. Alpha-Blockers: Caution is advised when PDE5 inhibitors are coadministered with alpha-blockers. QT Prolongation: Patients with congenital QT syndrome or taking class IA or III antiarrhythmics should avoid using vardenafil orally disintegrating tablet. Phenylketonurics: Each vardenafil orally disintegrating tablet contains 3.36 mg phenylalanine per tablet, which could be harmful for patients with phenylketonuria. Adverse reactions reported by ≥ 2% of patients treated with vardenafil orally disintegrating tablet: Headache, flushing, nasal congestion, dyspepsia, dizziness, back pain. Vardenafil orally disintegrating tablet should be placed on the tongue where it will disintegrate. Vardenafil orally disintegrating tablet may be taken with or without food.

Programar Citas para el Tratamiento de la DE en New York Urology Specialists

(2.2)DOSAGE FORMS AND STRENGTHSVardenafil orally disintegrating tablet 10 mg: White to off-white, round, biconvex, orally disintegrating tablets (not scored) (3)CONTRAINDICATIONSWARNINGS AND PRECAUTIONSCardiovascular Effects: Patients should not use vardenafil orally disintegrating tablet if sex is inadvisable due to cardiovascular status. (5.1)Strong and Moderate CYP3A4 Inhibitors: Do not use vardenafil orally disintegrating tablet in patients taking strong or moderate CYP3A4 inhibitors. (5.2, 7.2)Risk of Priapism: In the event that an erection lasts more than 4 hours, the patient should seek immediate medical assistance. (5.3)Effects on the Eye: Patients should stop use of vardenafil orally disintegrating tablet, and seek medical attention in the event of sudden loss of vision in one or both eyes, which could be a sign of non arteritic anterior ischemic optic neuropathy (NAION). Vardenafil orally disintegrating tablet should be used with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION.

If you develop priapism

Patients with a “crowded” optic disc may also be at an increased risk of NAION. (5.4, 6.2)Sudden Hearing Loss: Patients should stop vardenafil orally disintegrating tablet and seek medical attention in the event of sudden decrease or loss in hearing. (5.5, 6.2)Alpha-Blockers: Caution is advised when PDE5 inhibitors are coadministered with alpha-blockers. In some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (for example, fainting). In patients taking alpha-blockers, do not initiate vardenafil therapy with vardenafil orally disintegrating tablet. Vardenafil orally disintegrating tablet 10 mg: White to off-white, round, biconvex, orally disintegrating tablets (not scored) (3) Cardiovascular Effects: Patients should not use vardenafil orally disintegrating tablet if sex is inadvisable due to cardiovascular status.

Lea Historias reales de hombres que se sometieron a tratamiento para la DE en New York Urology Specialists.

To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc., at 1-888-943-3210 or 1-855-926-3384 or FDA at 1-800-FDA-1088 or Vardenafil orally disintegrating tablet can potentiate the hypotensive effects of nitrates, alpha-blockers, and antihypertensives. Do not use vardenafil orally disintegrating tablet with moderate or strong CYP3A4 inhibitors as coadministration will result in significant increases in plasma vardenafil concentrations. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved levitra for ed patient labeling. Table of Contents FULL PRESCRIBING INFORMATION: CONTENTS*1 INDICATIONS & USAGE2 DOSAGE & ADMINISTRATION2.1 General2.2 Use with Food2.3 Use in Special Populations2.4 Concomitant Medications3 DOSAGE FORMS & STRENGTHS4 CONTRAINDICATIONS4.1 Nitrates4.2 Guanylate Cyclase (GC) Stimulators5 WARNINGS AND PRECAUTIONS5.1 Cardiovascular Effects5.2 Potential for Drug Interactions with Strong or Moderate CYP3A4 Inhibitors5.3 Risk of Priapism5.4 Effects on the Eye5.5 Sudden Hearing Loss5.6 Alpha-Blockers5.7 Congenital or Acquired QT Prolongation5.8 Hepatic Impairment5.9 Renal Impairment5.10 Combination with Other Erectile Dysfunction Therapies5.11 Effects on Bleeding5.12 Phenylketonurics5.13 Fructose Intolerance5.14 Sexually Transmitted Disease6 ADVERSE REACTIONS6.1 Clinical Studies Experience6.2 Postmarketing Experience7 DRUG INTERACTIONS7.1 Potential for Pharmacodynamic Interactions with vardenafil orally disintegrating tablet7.2 Effect of Other Drugs on Vardenafil7.3 Effects of Vardenafil on Other Drugs8 USE IN SPECIFIC POPULATIONS8.1 Pregnancy8.2 Lactation8.4 Pediatric Use8.5 Geriatric Use8.6 Hepatic Impairment8.7 Renal Impairment10 OVERDOSAGE11 DESCRIPTION12 CLINICAL PHARMACOLOGY12.1 Mechanism of Action12.2 Pharmacodynamics12.3 Pharmacokinetics13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis & Mutagenesis & Impairment of Fertility14 CLINICAL STUDIES14.1 Other Vardenafil Clinical Trials Using Film-Coated Tablets16 HOW SUPPLIED/STORAGE AND HANDLING16.1 How Supplied16.2 Recommended Storage17 PATIENT COUNSELING INFORMATION*Sections or subsections omitted from the full prescribing information are not listed. Sections or subsections omitted from the full prescribing information are not listed.

Phosphodiesterase type V inhibitors: occurrence and fate in wastewater and sewage sludge

2 DOSAGE & ADMINISTRATION 2.1 GeneralVardenafil is available in 10 mg orally disintegrating tablets. Vardenafil orally disintegrating tabletis not interchangeable with vardenafil 10 mg film-coated tablets (LEVITRA). Vardenafil orally disintegrating tabletprovides higher systemic exposure compared to vardenafil 10 mg film-coated tablets (LEVITRA). ]Vardenafil orally disintegrating tablet should be taken orally, as needed, approximately 60 minutes before sexual activity. The maximum dosing frequency is one Vardenafil orally disintegrating tablet per day. Strong and Moderate CYP3A4 Inhibitors: Do not use vardenafil orally disintegrating tablet in patients taking strong or moderate CYP3A4 inhibitors. Risk of Priapism: In the event that an erection lasts more than 4 hours, the patient should seek immediate medical assistance. Effects on the Eye: Patients should stop use of vardenafil orally disintegrating tablet, and seek medical attention in the event of sudden loss of vision in one or both eyes, which could be a sign of non arteritic anterior ischemic optic neuropathy (NAION). Sudden Hearing Loss: Patients should stop vardenafil orally disintegrating tablet and seek medical attention in the event of sudden decrease or loss in hearing. Alpha-Blockers: Caution is advised when PDE5 inhibitors are coadministered with alpha-blockers.

• Liquid Levitra is often preferred for its ease of swallowing.
• It may be used when swallowing pills is difficult.
• Proper storage preserves its potency.

QT Prolongation: Patients with congenital QT syndrome or taking class IA or III antiarrhythmics should avoid using vardenafil orally disintegrating tablet.

Phenylketonurics: Each vardenafil orally disintegrating tablet contains 3.36 mg phenylalanine per tablet, which could be harmful for patients with phenylketonuria. Adverse reactions reported by ≥ 2% of patients treated with vardenafil orally disintegrating tablet: Headache, flushing, nasal congestion, dyspepsia, dizziness, back pain. To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc., at 1-888-943-3210 or 1-855-926-3384 or FDA at 1-800-FDA-1088 or Vardenafil orally disintegrating tablet can potentiate the hypotensive effects of nitrates, alpha-blockers, and antihypertensives. Do not use vardenafil orally disintegrating tablet with moderate or strong CYP3A4 inhibitors as coadministration will result in significant increases in plasma vardenafil concentrations. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved levitra for ed patient labeling. Table of Contents FULL PRESCRIBING INFORMATION: CONTENTS*1 INDICATIONS & USAGE2 DOSAGE & ADMINISTRATION2.1 General2.2 Use with Food2.3 Use in Special Populations2.4 Concomitant Medications3 DOSAGE FORMS & STRENGTHS4 CONTRAINDICATIONS4.1 Nitrates4.2 Guanylate Cyclase (GC) Stimulators5 WARNINGS AND PRECAUTIONS5.1 Cardiovascular Effects5.2 Potential for Drug Interactions with Strong or Moderate CYP3A4 Inhibitors5.3 Risk of Priapism5.4 Effects on the Eye5.5 Sudden Hearing Loss5.6 Alpha-Blockers5.7 Congenital or Acquired QT Prolongation5.8 Hepatic Impairment5.9 Renal Impairment5.10 Combination with Other Erectile Dysfunction Therapies5.11 Effects on Bleeding5.12 Phenylketonurics5.13 Fructose Intolerance5.14 Sexually Transmitted Disease6 ADVERSE REACTIONS6.1 Clinical Studies Experience6.2 Postmarketing Experience7 DRUG INTERACTIONS7.1 Potential for Pharmacodynamic Interactions with vardenafil orally disintegrating tablet7.2 Effect of Other Drugs on Vardenafil7.3 Effects of Vardenafil on Other Drugs8 USE IN SPECIFIC POPULATIONS8.1 Pregnancy8.2 Lactation8.4 Pediatric Use8.5 Geriatric Use8.6 Hepatic Impairment8.7 Renal Impairment10 OVERDOSAGE11 DESCRIPTION12 CLINICAL PHARMACOLOGY12.1 Mechanism of Action12.2 Pharmacodynamics12.3 Pharmacokinetics13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis & Mutagenesis & Impairment of Fertility14 CLINICAL STUDIES14.1 Other Vardenafil Clinical Trials Using Film-Coated Tablets16 HOW SUPPLIED/STORAGE AND HANDLING16.1 How Supplied16.2 Recommended Storage17 PATIENT COUNSELING INFORMATION*Sections or subsections omitted from the full prescribing information are not listed. Sections or subsections omitted from the full prescribing information are not listed.

2 DOSAGE & ADMINISTRATION 2.1 GeneralVardenafil is available in 10 mg orally disintegrating tablets. Vardenafil orally disintegrating tabletis not interchangeable with vardenafil 10 mg film-coated tablets (LEVITRA). Vardenafil orally disintegrating tabletprovides higher systemic exposure compared to vardenafil 10 mg film-coated tablets (LEVITRA). ]Vardenafil orally disintegrating tablet should be taken orally, as needed, approximately 60 minutes before sexual activity. The maximum dosing frequency is one Vardenafil orally disintegrating tablet per day. Sexual stimulation is required for a response to treatment.Vardenafil orally disintegrating tabletshould be placed on the tongue where it will disintegrate. It should be taken immediately upon removal from the blister.Those patients who require a lower or higher dose of vardenafil need to be prescribed vardenafil film-coated tablets [see Patient Counseling Information (17)] .2.3 Use in Special PopulationsHepatic Impairment: Do not use vardenafil orally disintegrating tabletin patients with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment [see Warnings and Precautions (5.8) and Clinical Pharmacology (12.3)] .Renal Impairment: Do not use vardenafil orally disintegrating tablet in patients on renal dialysis [see Warnings and Precautions (5.9) and Clinical Pharmacology (12.3)].2.4 Concomitant MedicationsNitrates: Concomitant use with nitrates in any form is contraindicated [see Contraindications (4.1)] .Guanylate Cyclase (GC) Stimulators, such as riociguat: Concomitant use is contraindicated [see Contraindications (4.2)].CYP3A4 Inhibitors: Do not use vardenafil orally disintegrating tablet with strong or moderate CYP3A4 inhibitors such as cobicistat ,ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, atazanavir, clarithromycin and erythromycin [see Warnings and Precautions (5.2) and Drug Interactions (7.2)].Alpha-Blockers: In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest recommended starting dose. Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure in patients taking a phosphodiesterase (PDE5) inhibitor including vardenafil. Lower doses of vardenafil film-coated tablets should be used as initial therapy in these patients [see Dosage and Administration (2.4)] .Patients taking alpha-blockers who have previously used vardenafil film-coated tablets may change to vardenafil orally disintegrating tablet at the advice of their healthcare provider. [See Warnings and Precautions (5.6) and Drug Interactions (7.1).

• Liquid Levitra should be measured with a proper device.
• Avoid mixing with hot liquids to prevent degradation.
• Keep the medication stored at room temperature.

]A time interval between dosing should be considered when vardenafil orally disintegrating tablet is prescribed concomitantly with alpha-blocker therapy [see Clinical Pharmacology (12.2)].